CAMBRIDGE, Mass. - Moderna has passed a major milestone on its path to getting its COVID-19 vaccine fully approved by the U.S.
Food and Drug Administration.The pharmaceutical company announced Wednesday that it completed the rolling submission process for its Biologics License Application.
The BLA, which Moderna began on June 1, involves submitting nonclinical and clinical data to support the licensure of the COVID-19 vaccine.Now that it’s complete, Moderna has asked the FDA for priority review.
Once granted, that would allow the FDA to take action within a six-month window, rather than the typical 10-month time frame.In a news release, Stéphane Bancel, Chief Executive Officer of Moderna, said the company began its BLA process in June.